Phase I trial of interleukin-2 and high-dose arginine butyrate in metastatic colorectal cancer

Cancer Immunology Immunotherapy

Volumn 49, Issue 1, 2000, Pages 56-61

  Douillard, J Y ^a   Bennouna, J ^a   Vavasseur, F ^b   Deporte Fety, R ^a   Thomare, P ^c   Giacalone, F ^a   Meflah, K ^b  

^a CENTRE RENÉ GAUDUCHEAU   (France)

^b INSERM   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

Apoptosis; Arginine butyrate; Cell differentiation; Colorectal cancer; IL 2; Immune stimulation

Indexed keywords

ARGININE BUTYRATE; ARGININE DERIVATIVE; RECOMBINANT INTERLEUKIN 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; LIVER FAILURE; LIVER TOXICITY; MALE; METASTASIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0033935139     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050026     Document Type: Article

References (12)

1. Boisteau O, Gautier F, Cordel S, Henry F, Harb J, Douillard JY, Vallette FM, Meflah K, Grégoire M (1997) Apoptosis induced by sodium butyrate treatment increases immunogenicity of a rat colon tumor cell line. Apoptosis 2:403-412
2. Braga AC, Vilarinho L, Ferreira E, Rocha H (1997) Hyperargininemia presenting as persistent neonatal jaundice and hepatic cirrhosis. J Pediatr Gastroenterol Nutr 24:218-221
3. Braut-Boucher F, Pichon J, Rat P, Adolphe M, Aubery M, Font J (1995) A non isotopic, highly sensitive, fluorimetric, cell- cell adhesion microplate assay using calecin AM-labeled lymphocytes. J Immunol Method 178:41-51
4. Estève J, Kricker A, Ferlay J, Parkin DM (1993) Facts and figures of cancer in the European Community. IARC Sci Publ 121
5. Garnet L, Daviaud D, Denis-Pouxviel C, Remesy C, Murat JC (1992) Effect of short-chain fatty acids on growth and differenciation of the human colon-cancer cell line HT29. Int J Cancer 52:286-289
6. Heys SD, Segar A, Payne S, Bruce DM, Kernohan N, Eremin O (1997) Dietary supplementation with L-arginine: Modulation of tumor-infiltrating lymphocytes in patients with colorectal cancer. Br J Surg 84:238-241
7. Miller AA, Kurschel E, Osieka R, Schmidt CG (1987) Clinical pharmacology of sodium butyrate in patients with acute leukemia. Eur J Cancer Clin Oncol 23:1283-1287
8. Moebius U, Gunzler V, Hanauske-Abel HM, Spaeth E, Rude E, Tschank G (1987) Butyrate-synchronized cloned T cells retain their dependence on interleukine-2 for growth induction. A model system for growth regulation. Exp Cell Res 169:379-384
9. Orien S, Micropharm K (1995) A microcomputer interactive program for the analysis and simulation of pharmacokinetic processes. Pharm Res 12:1225-1230
10. Perrin P, Cassagnau E, Burg C, Patry Y, Vavasseur F, Harb J, Le Pendu J, Douillard JY, Galmiche JP, Bornet F, Meflah K (1994) An interleukine 2/sodium butyrate combination as immunotherapy for rat colon cancer peritoneal carcinomatosis. Gastroenterology 107:1697-1708
11. Perrine SP, Ginder GD, Faller DV, Dover GH, Ikuta T, Witkowska HE, Cai SP, Vichinsky EP, Oliviery NF (1993) A short-term trial of butyrate to stimulate fetal-globin-gene expression in the β-globin disorders. N Engl J Med 328:81-6
12. Rosenberg SA, Lotze MT, Mull LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukine-2 or high-dose interleukine-2. N Engl J Med 316:889-897